Elevate the Potential of Your Clinical Trial

Kent Hendrix

Kent Hendrix has 33 years experience in the Pharmaceutical industry, including all aspects of statistical programming in SAS, and has handled a broad variety of clinical trials and data analysis projects. He has worked on many NDAs and managed multiple groups of SAS programmers. Mr. Hendrix has taught SAS programming at Brigham Young University and AP Statistics and Computer Science at the high school level. Mr. Hendrix also developed a SAS program Log File Analysis tool that helps SAS programmers debug their code faster. Additionally, Kent developed a web-based clinical trial management software that handles the enrollment and randomization of subjects, drug distribution to sites, and allocation to subjects. This software has managed global phases I, II, and III clinical trials. As one of the founders of Pentara, Kent has loved watching the company grow. He loves that Pentara makes a “disproportionately large splash in the field compared to our size. We really change the world.” When he isn’t working, Mr. Hendrix can be found teaching Bushikai Kishindo Martial Arts, in which he holds a 10th degree black belt. He also enjoys reading and fishing in the beautiful Utah mountains.

Samuel Dickson

Sam Dickson has a Ph.D. in statistics and bioinformatics and has been working in clinical trials since 2003. As Vice President of Statistics at Pentara Corporation, he consults with clients on study design and analysis of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and ALS. One area of particular interest to Dr. Dickson is finding or developing appropriate and meaningful outcomes to be able to detect treatment effects in progressive diseases, which are generally heterogeneous and difficult to measure with precision. He is an expert in clinical trial design for phase 2 and phase 3 clinical trials, including group sequential designs, sample size re-estimation, and Bayesian adaptive studies. His background includes experience working with research and clinical data at GlaxoSmithKline, Duke University, the United States Army, Pfizer, and a public health company. Dr. Dickson has worked on treatments for a wide range of conditions including the Ebola virus, malaria, dengue, macular degeneration, pain, schizophrenia, laser hair removal, and other cosmetic devices. He also has experience with whole genome and exome sequencing data and helped to develop a polygenic risk score for Alzheimer's disease. Dr. Dickson believes everyone was born Bayesian.

Jessie Nicodemus-Johnson

Jessie Nicodemus Johnson is the Senior Director of Statistics at Pentara Corporation. She joined Pentara Corporation in 2020, bringing over 15 years of experience in statistics, study design, and integrative physiology. Jessie and her team manage a diverse array of client needs including clinical trial design, CDISC dataset generation, Ad Hoc analyses supportive of study design, and post hoc analyses of study outcomes. Jessie specializes in incorporating the clinical and underlying molecular aspects of treatment efficacy with statistical methodology resulting in a more thorough understanding of associations with outcomes of interest. Jessie received her PhD in Molecular and Integrative Physiology from the University of Illinois: Urbana-Champaign in 2010 and continued to cultivate her understanding and love of systems biology and statistics during her postdoc at the University of Chicago in the Department of Human Genetics. When not working, Jessie enjoys spending time with her kids in the mountains surrounding Salt Lake City.

Craig Mallinckrodt

Craig is a Distinguished Biostatistician at Pentara where he contributes broadly to support client’s research in Alzheimer’s and other diseases. Craig joined Pentara in 2022 after 30 years of clinical trial experience in academia and at large and small pharma companies. He is a Fellow of the American Statistical Association and won the Royal Statistical Society’s award for Outstanding Contribution to the Pharmaceutical Industry. Dr. Mallinckrodt led the statistical work that resulted in global regulatory approvals for drugs in 10 indications. Craig also led industry working groups on methodology topics, including placebo response, missing data, and estimands and sensitivity analyses. He has authored four books and 200 manuscripts on various statistical and clinical topics. Dr. Mallinckrodt led much of the early research into the MMRM analytic approach that resulted in this method’s widespread use in longitudinal clinical trials. A native of Missouri and long-time resident of Colorado, where he got his BS, MS, and PhD (1993) at Colorado State University, Craig now resides with his wife Donna in Indianapolis, IN. Donna is a licensed Medicare Insurance Specialist with a passion for helping the elderly. Their daughter, Marissa, is a nurse in Chicago where she continues Donna’s passion for helping others. Craig enjoys running, having logged over 100,000 miles lifetime, and winning a bronze medal at the 1996 Paralympics. He also enjoys cycling, skiing and wildlife photography.

Christina Pick

Christina Pick is the Director of Clinical Programming at Pentara. She leads a team of programmers that creates submission-ready SDTM packages and provides programming support for data review and cleaning. Christina earned a Master's degree in Statistics from the University of Utah which ensures each of her projects have the end analyses in mind even if the specific work being done does not involve statistics. She has provided SDTM dataset for multiple FDA submissions. During her time in this industry, Christina has learned the importance of applying CDISC standards as early in the process as possible such that the protocol and EDC build lead to smooth transition from raw to SDTM data. She is passionate about findings new ways to automate tedious tasks to ensure the accuracy and efficiency of her team.

Newman Knowlton

VP of Corporate Development Newman Knowlton received his Master’s degree in Quantitative Psychology from McGill University in Montreal, Quebec in 2017. Mr. Knowlton started working at Pentara in January of 2018 as Pentara’s fifth employee. While at Pentara, he has presented at several conferences, contributed to several papers, and was the lead on an NDA for an ALS drug (AMX0035). Since he was one of the first to join the Pentara team, Newman’s favorite thing about the company is seeing it grow. He takes pride in Pentara’s work and is happy to see the team getting bigger and receiving more recognition. Outside of the office, Newman enjoys yoga, and civil engineering, as well as playing tennis and renovating houses. Among all of his hobbies and talents, Newman is the most proud of his 1996 Honda Civic.

Jeffery Yearley

Jeffery Yearley is a strategic leader with over 20 years of experience in data management, governance, and quality assurance. His expertise is focused on designing and implementing enterprise-wide Quality Management Systems (QMS) and data governance frameworks that ensure regulatory compliance (GCP, 21 CFR Part 11, GDPR, ISO 27001). He has a proven track record of modernizing data platforms to enable innovation and growth, building high-performing teams, and fostering a culture of data quality and excellence. His work has significantly enhanced data governance maturity, security, and accessibility across clinical research and life sciences organizations.